IFNA1 and influenza: The incidence of AEs known or suspected to be associated with IFN therapy, such as influenza-like symptoms, injection-site reactions, hepatic abnormalities (particularly elevated transaminase levels), cytopenias and depression, was higher in the IFN beta-1a treatment groups than the placebo group, but was consistent with previous experience with IFN therapy.